(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Doritos and Cheetos dial back the bright orange in new versions without artificial ingredients - 2German economic institutes cut forecast in half over Iran war
- 3Striking American and European television Projects: A Survey
- 4Cyber Monday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- 5More Than 110 New Species Discovered In Deep Waters Off Australia
- Polish law aimed at lowering petrol prices takes effect
- Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- 10 Natural products to Remember for Your Eating routine for a Better You
- NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
- The Most Important Crossroads in Olympic History
- 'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
- Israeli forces kill one person in series of attacks on southern Lebanon
- Italy's Beloved Trevi Fountain Hides A Unique Secret That Can Be Explored Underground
- Most loved Web-based feature: Which Stage Do You Like
